SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.42 CNY | -10.90% |
|
-4.05% | -41.53% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Shanghai Yizhong Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development and industrialization of new and improved anti-tumor drugs. The Company's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -41.53% | 818M | |
| +12.55% | 9.06B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +20.51% | 2.41B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B | |
| +3.94% | 1.65B |
- Stock Market
- Equities
- 688091 Stock
- News Shanghai Yizhong Pharmaceutical Co., Ltd.
- Yizhong Pharmaceutical's Plant Passes Good Manufacturing Practice Inspection of Shanghai's Drug Regulator
